6 drug(s) with this reaction
2,714 total reports
Pancytopenia has been reported as an adverse reaction across 6 drug(s) manufactured by Amgen Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 2,714 adverse event reports mention pancytopenia in connection with Amgen Inc products.
This page provides a breakdown of which Amgen Inc drugs are most commonly associated with pancytopenia, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Amgen Inc drugs have pancytopenia listed in their FDA adverse event reports, sorted by report count:
In addition to pancytopenia, the following adverse reactions have been reported across Amgen Inc's drug portfolio:
6 drug(s) manufactured by Amgen Inc have pancytopenia listed in their FDA adverse event reports: FILGRASTIM, PEGFILGRASTIM, DARBEPOETIN ALFA, EPOETIN ALFA, BLINATUMOMAB, and others.
There are a combined 2,714 reports of pancytopenia across 6 Amgen Inc drug(s) in the FDA adverse event database.